D-NAME (hydrochloride) (Synonyms: D-NG-Nitroarginine methyl ester, N(G)-Nitro-D-Arginine methyl ester) |
رقم الكتالوجGC19437
One-Click Copy Product Info
|
N(G)-Nitro-D-arginine methyl ester (D-NAME) is the less active enantiomer of the nitric oxide (NO) synthase inhibitor N(G)-nitro-L-arginine methyl ester .
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 50912-92-0
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
N(G)-Nitro-D-arginine methyl ester (D-NAME) is the less active enantiomer of the nitric oxide (NO) synthase inhibitor N(G)-nitro-L-arginine methyl ester . D-NAME was initially thought to be inactive and was often used as a negative control for L-NAME. Later studies showed that D-NAME (40 mg/kg/day in rats) can have similar but less pronounced effects as L-NAME (40 mg/kg/day in rats) in the cardiovascular system, particularly at long-term timepoints. D-NAME (3-10 µg/mouse) had no effect on nociception in mice assessed using the tail flick test.
References:
[1].Palmer, R.M.J., Rees, D.D., Ashton, D.S., et al. L-arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation Biochem. Biophys. Res. Commun. 153(3), 1251-1256 (1988).
[2]. Chinellato, A., Froldi, G., Caparrota, L., et al. Pharmacological characterization of endothelial cell nitric oxide synthase inhibitors in isolated rabbit aorta Life Sci. 62(6), 479-490 (1998).
[3].Babál, P., Pechánová, O., and Bernátová, I. Long-term administration of D-NAME induces hemodynamic and structural changes in the cardiovascular system Physiol. Res. 49(1), 47-54 (2000).
[4].Kawabata, A., Umeda, N., and Takagaki, H. L-arginine exerts a dual role in nociceptive processing in the brain: Involvement of the kyotorphin-Met-enkephalin pathway and NO-cyclic GMP pathway Br. J. Pharmacol. 109(1), 73-79 (1993).
| Cas No. | 50912-92-0 | SDF | |
| المرادفات | D-NG-Nitroarginine methyl ester, N(G)-Nitro-D-Arginine methyl ester | ||
| Canonical SMILES | [H]N(/C(N([H])CCC[C@@H](N)C(OC)=O)=N/[H])[N+]([O-])=O.Cl | ||
| Formula | C7H15N5O4 • HCl | M.Wt | 269.7 |
| الذوبان | DMF: 20 mg/ml,DMSO: 20 mg/ml,PBS (pH 7.2): 10 mg/ml | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.7078 mL | 18.5391 mL | 37.0782 mL |
| 5 mM | 741.6 μL | 3.7078 mL | 7.4156 mL |
| 10 mM | 370.8 μL | 1.8539 mL | 3.7078 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 15 reference(s) in Google Scholar.)